Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Curtis A Lachowiez, Joshua F Zeidner, Ashley M. Eckel, Daniel T Peters, Jacob Fang, Amenech Ashango, Andy Kaempf, Fangyan Dai, Christopher A. Eide, Stephen E. Kurtz, Theodore P Braun, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Daniel A Pollyea

Blood (2024) 144 (Supplement 1): 62.

https://doi.org/10.1182/blood-2024-201532

Published: 2024

Journal Articles

Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia

Melissa L Stewart, Jessica Gibbs, Daniel Bottomly, Andy Kaempf, Stephen E. Kurtz, Christopher A. Eide, Ariane Huang, Luca Sax, Nicola Long, Shannon K McWeeney, Bill H Chang, Jeffrey W. Tyner

Blood (2024) 144 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2024-198516

Published: 2024

Journal Articles

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Jennifer N. Saultz, Manoj Rai, Andy Kaempf, Sanjog Bastola, Hyun Cho, Nicola Long, Curtis A. Lachowiez, Gabrielle Meyers, Jessica T. Leonard, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner

Blood (2024) 144 (Supplement 1): 2859.

https://doi.org/10.1182/blood-2024-211860

Published: 2024

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2024-208505

Published: 2024

Journal Articles

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

Bridget A Robinson, Philipp Sergeev, Yoko Kosaka, Thomas Jacob, Andy Kaempf, Evan F. Lind, Cristina Tognon, Luis A. Carvajal, Jorge F. DiMartino, Caroline A. Heckman, Tania Q Vu

Blood (2023) 142 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2023-186506

Published: 2023

Journal Articles

Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph+ Acute Lymphoblastic Leukemia

Simone E. Dekker, Jean Sabile, Brandon Dasilva, Caner Saygin, Marc Schwartz, Hari S. Raman, Andy Kaempf, Marlise R Luskin, Anand Ashwin Patel, Lori S. Muffly, Jessica T. Leonard

Blood (2023) 142 (Supplement 1): 6061.

https://doi.org/10.1182/blood-2023-185040

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Blood (2022) 140 (Supplement 1): 2048–2050.

https://doi.org/10.1182/blood-2022-169872

Published: 2022

Journal Articles

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Jennifer N. Saultz, Daniel Bottomly, Faith Burns, Kaelan Byrd, Yoko Kosaka, Shannon K. McWeeney, Stephen E. Kurtz, Guang Fan, Andy Kaempf, Karen McGovern, Lei Wang, Marta Sanchez-Martin, Dan S Kaufman, Evan F. Lind, Jeffrey W. Tyner

Blood (2022) 140 (Supplement 1): 3071–3072.

https://doi.org/10.1182/blood-2022-163166

Published: 2022

Journal Articles

Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy

Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Sunil K Joshi, Tamilla Nechiporuk, Ariane Huang, Charles Dibb, Daniel Bottomly, Shannon K. McWeeney, Bill H. Chang, Brian J. Druker, Jeffrey W. Tyner

Blood (2022) 140 (Supplement 1): 1025–1027.

https://doi.org/10.1182/blood-2022-159264

Published: 2022

Journal Articles

A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS)

Jean M.G. Sabile, Andy Kaempf, Kaitlyn Tomic, Gurusidda Manu, Ronan T. Swords, Yazan Migdady

Blood (2022) 140 (Supplement 1): 4088–4089.

https://doi.org/10.1182/blood-2022-159335

Published: 2022

Journal Articles

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Uma Borate, Jennifer N. Saultz, Andy Kaempf, Jessica Minnier, Cristina E. Tognon, Stephen E. Kurtz, Christopher A. Eide, Prapti A. Patel, Yazan F. Madanat, Peter Clement, Sammantha Avaylon, Shikha Misra, Brian J. Druker, Jeffrey W. Tyner

Blood (2021) 138 (Supplement 1): 2333.

https://doi.org/10.1182/blood-2021-152903

Published: 2021

Journal Articles

Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study

Blood (2021) 138 (Supplement 1): 529.

https://doi.org/10.1182/blood-2021-149735

Published: 2021

Journal Articles

Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

Max J. Gordon, Andy Kaempf, Emelie Rotbain, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Michael Choi, Jonathon B. Cohen, Deborah M. Stephens, Dan O. Persky, Krish Patel, Mazyar Shadman, Byung Park, Carsten Utoft Niemann, Alexey V. Danilov

Blood (2021) 138 (Supplement 1): 2637.

https://doi.org/10.1182/blood-2021-148253

Published: 2021

Journal Articles

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Uma Borate, Andy Kaempf, Jessica Minnier, Shikha Misra, Shaun Goodyear, Gabrielle Meyers, Jennifer N. Saultz, Elie Traer, Ronan Swords, Rachel J. Cook, Sammantha Avaylon, Melissa Mackey, Brianna Norris, Roland B. Walter

Blood (2021) 138 (Supplement 1): 1269.

https://doi.org/10.1182/blood-2021-152791

Published: 2021

Journal Articles

Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia

Christopher A. Eide, Stephen E. Kurtz, Andy Kaempf, Nicola Long, Daniel Bottomly, Olga Nikolova, Brian J. Druker, Shannon K. McWeeney, Jeffrey W. Tyner, Anupriya Agarwal

Blood (2021) 138 (Supplement 1): 1301.

https://doi.org/10.1182/blood-2021-152043

Published: 2021

Journal Articles

Evolution of Gilteritinib Resistance from Residual Disease to Relapse

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-139084

Published: 2020

NARROW

Influence of AML Differentiation State in Risk Stratification of Frontline Therapy with Hypomethylating Agents + Venetoclax in AML

Combination with Palbociclib Overcomes Venetoclax Resistance Mechanisms and Outperforms Single Agent Efficacy in Acute Myeloid Leukemia

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Combined Single Cell Flow Cytometry and Imaging Analyses Reveal Immunomodulatory Effects Exerted By Targeted Phospho-SYK Inhibitors with Elevated Sensitivity in NPM1 Mutated AML

Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph+ Acute Lymphoblastic Leukemia

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy

A Retrospective Validation Study Comparing the IPSS-M and IPSS-R Risk Stratification Scores in Primary and Secondary Myelodysplastic Syndrome (MDS)

Novel Combination Therapy of Venetoclax and Ruxolitinib in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia

Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study

Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy

Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia

Evolution of Gilteritinib Resistance from Residual Disease to Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only